Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 04 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Safety and efficacy of different lanreotide doses for polycystic liver disease

This month's issue of the Alimentary Pharmacology & Therapeutics investigates the safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease.

News image

Long-acting lanreotide 120 mg every 4 weeks reduces liver volume in patients with polycystic liver diseases.

Animal studies that demonstrated that the inhibition of hepatic and renal cystogenesis is dose dependent.

Dr Temmerman and colleagues from Belgium investigated the safety and efficacy of two different LAN doses in polycystic liver diseases patients.

The 6-month results of the LOCKCYST I trial, its extension study, and the LOCKCYST II trial were pooled.

Long-acting lanreotide at baseline and month 6 was measured by CT-scan and blindly re-analyzed by 2 independent radiologists.

Severe side effects with long-acting lanreotide 120 mg was 16%
Alimentary Pharmacology & Therapeutics

The study population consisted of 3 groups.

Each received treatment every 4 weeks during 6 months plus placebo, or long-acting lanreotide at 90 mg or 120 mg.

The team reported excellent inter-observer variability and agreement in the calculation of Long-acting lanreotide.

The researchers observed that severe side effects with placebo, long-acting lanreotide 90 mg and 120 mg were 0%, 7% and 16%, respectively.

Change in long-acting lanreotide after 6 months in these 3 groups included an increase of +36 mL, decrease of −82 mL, and decrease of -123 mL, respecitvely.

Based on ROC analysis, a reduction of 120 mL or more in liver volume has a positive predictive value of 64% for improving symptoms.

Dr Temmerman's team concludes, "Both long-acting lanreotide 90 mg and long-acting lanreotide120 mg reduce liver volume."

"Long-acting lanreotide 90 mg has less side effects. "

"This suggests that in case of intolerance to long-acting lanreotide 120 mg, a dose reduction to long-acting lanreotide 90 mg is meaningful."

Aliment Pharmacol Ther 2013: 38(4): 397–406
06 August 2013

Go to top of page Email this page Email this page to a colleague

 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants
 08 November 2016 
NSAIDS and risk of Barrett’s
 08 November 2016 
Ferritin levels and NAFLD mortality
 08 November 2016 
Alarms in the diagnosis of colorectal cancer
 07 November 2016 
BMI and fibrosis regression during Hep B
 07 November 2016 
Prognosis and biliary tract malignancies
 07 November 2016 
Post-colonoscopy colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us